Orphan drug company Alexion Pharmaceuticals (ALXN) could be in its third year of flat profit growth. Plus, political concerns are putting pressure on drug prices and drugs stocks as well.

Alexion Pharmaceuticals (ALXN) should have three blockbuster drugs in the coming years, but right now ALXN stock isn’t doing much.

It will take a while before we know if Alexion’s (ALXN) deal for Synageva is worth the price.

Alexion (ALXN) had to (over)pay to play, but now has 2 potential blockbusters in its portfolio.

Last qtr Alexion Pharmaceuticals (ALXN) broke out, but now that momentum has stalled.

Yesterday Alexion Pharmaceuticals (ALXN) broke out to $200. My 2016 Fair Value is $280. Let me show you.

Alexion Pharmaceuticals (ALXN) is doing well right now, but the stock’s not moving, so I’ll sell ALXN from the Aggressive Growth Portfolio.

Bietech stocks are in a correction and I’m taking the opportunity to buy Alexion Pharmaceuticals (ALXN) on a dip.